EXBLIFEP treatment is indicated for usage in patients aged 18 years and above with complicated urinary tract infections. Credit: Albina Gavrilovic / Shutterstock.com.

The US Food and Drug Administration (FDA) has approved Allecra Therapeutics’ EXBLIFEP (cefepime/enmetazobactam) to treat complicated urinary tract infections (cUTIs) including pyelonephritis.

EXBLIFEP is indicated for patients aged 18 years and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The approval is accompanied by a five-year marketing exclusivity extension from the US regulator under the Generating Antibiotic Incentives Now (GAIN) Act.

The GAIN Act offers incentives for developing new anti-infective drugs by granting benefits to qualified infectious disease product manufacturers.

The FDA granted the approval based on comprehensive clinical data highlighting the effectiveness of EXBLIFEP  against antimicrobial resistance in gram-negative bacteria, particularly resistance caused by extended spectrum beta lactamases and ampC enzymes.

The data included results from the Phase III ALLIUM clinical trial in which EXBLIFEP demonstrated superiority to piperacillin/tazobactam in clinical cure and microbiological eradication in cUTI patients.

Allecra holds an extensive patent estate for the therapy in key markets, with the GAIN Act extending market exclusivity until 2032.

Orchid Pharma discovered enmetazobactam, a component of EXBLIFEP, and assigned all rights outside India to Allecra Therapeutics in 2013.

Since then, Allecra has been solely responsible for the global clinical and regulatory development of EXBLIFEP.

The company has completed exclusive licensing agreements with Shanghai Haini Pharmaceutical in Greater China and ADVANZ PHARMA in Europe.

In another global Phase III trial, EXBLIFEP was analysed against piperacillin / tazobactam, a standard cUTI care, showcasing its potential in a randomised, controlled, double-blind setting.

Allecra’s commercial partner, Advanz Pharma, sought marketing authorisation for EXBLIFEP in Europe.

Allecra Therapeutics supervisory board member Iain Buchanan said: “Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small yet highly focused team of individuals.

“As we continue our discussions with strategic partners for product launch in the US, we value the FDA’s positive decision on EXBLIFEP’s ability to address a critical unmet medical need for patients.”